Formycon AG

FYB · Xetra

Public Market Listing

FYBXetra

Xetra primary exchange listing

Live quotes, historical charts, and market capitalization for Formycon AG are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(3 total)
3Total Assets
3Approved
0Phase 3 / Filed
0Phase 1–2 / Early
5Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Approved
VEGF-AProtein / enzyme therapeutic
Age-Related Macular DegenerationDiabetic Macular Edema
Wet Age-Related Macular Degeneration
Approved
VEGF-AMonoclonal antibody
Age-Related Macular DegenerationDiabetic Macular Edema
Wet Age-Related Macular Degeneration
Approved
IL-12 p40
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis
Ulcerative Colitis, Crohn's Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$50M—$81M—report ↗